February 2014 | The Journal of Targeted Therapies in Cancer

Eribulin Shows First-Line Activity in MBC

March 03, 2014

Clinical Articles

Eribulin mesylate has demonstrated clinical benefit as a first-line therapy for locally recurrent or metastatic HER2- negative breast cancer, according to results of a phase II, multicenter, single-arm study.

Tailoring Treatments in HER2-Positive Breast Cancer

February 21, 2014

Clinical Articles

Significant developments in research and treatment for HER2-positive breast cancer have emerged over the past year. Those advances include a growing number of studies measuring the effectiveness of dual agents.

Manageable Safety Profile Determined in BOLERO-3

February 17, 2014

Clinical Articles

Previously revealed efficacy data from the BOLERO-3 study indicated slowed tumor progression in patients with trastuzumab-resistant HER2+ breast cancer, and now everolimus, trastuzumab, and vinorelbine has demonstrated a manageable safety profile.

Therapies for Breast Cancer: Practice-Changing Developments

February 14, 2014

Clinical Articles

Neoadjuvant and adjuvant therapies, administered before and after primary anticancer therapy, respectively, have been shown in numerous clinical trials to reduce recurrence and improve survival in patients with breast cancer.